Therapeutic Potential of Metabolites from Lactobacillus rhamnosus and Mare’s Milk in the Treatment of Dysbiosis

• Published in: BioMed research international 2022-01, Vol.2022, p.3851478-8
• Main Authors: Kozhakhmetov, Samat, Babenko, Dmitriy, Kozhakhmetova, Saniya, Tuyakova, Altynay, Nurgaziyev, Madiyar, Nurgozhina, Ayaulym, Muhanbetganov, Nurislam, Chulenbayeva, Laura, Sergazy, Shynggys, Gulyayev, Alexander, Aljofan, Mohamad, Kushugulova, Almagul
• Format: Article
• Language: English
• Subjects: Animals; Antimicrobial agents; Bacteria; Biodiversity; Care and treatment; Chemical properties; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - metabolism; Colitis, Ulcerative - microbiology; Colon; Cytokines; Cytokines - metabolism; Dextran; Dextran Sulfate; Dextrans; Discriminant analysis; Disease Models, Animal; Drinking water; Dysbacteriosis; Dysbiosis; Dysbiosis - drug therapy; E coli; Feces; Gastrointestinal Microbiome - drug effects; Health aspects; Horses; Inflammatory bowel disease; Inflammatory bowel diseases; Intestinal microflora; Intestine; Lactobacilli; Lactobacillus; Lactobacillus rhamnosus; Lactobacillus rhamnosus - metabolism; Mesalamine - pharmacology; Metabolites; Microbiomes; Microbiota; Microbiota (Symbiotic organisms); Microorganisms; Milk; Milk - metabolism; Pathogenesis; Physiological aspects; Rats; Rats, Wistar; Remission; rRNA 16S; Salmonella; Taxonomy; Ulcerative colitis
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2022/3851478

Ulcerative colitis is an inflammatory bowel disease that forms ulcerations in the mucous membrane of the colon and rectum, in which gut microbiota plays a pivotal role in its pathogenesis. Agents modulating microbial dysbiosis caused by colitis can help in the remission of this disease. The current study describes the potential therapeutic effects of active metabolites from Lactobacillus rhamnosus and mare’s milk which have potential therapeutic values on the intestinal microbiota and proinflammatory cytokines. The analysis of the V1-V3 16S rDNA site revealed significant changes in the intestinal microbiome composition before and after treatment in the treated group compared to the positive control group that was treated with 5-aminosalicylic acid (5-ASA). So the effect of the study product on dextran sulfate sodium-induced dysbiosis was shown to be more potent than the positive control, 5-ASA. The level of proinflammatory cytokines also decreased under the influence of a biological product.